Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2018 | 47 | 0.72 | Why? |
| Herpesvirus 8, Human | 1 | 2018 | 97 | 0.68 | Why? |
| DNA, Viral | 2 | 2018 | 2521 | 0.66 | Why? |
| Adenoviruses, Human | 1 | 2018 | 195 | 0.63 | Why? |
| Herpes Genitalis | 2 | 2014 | 90 | 0.63 | Why? |
| Herpesviridae Infections | 1 | 2018 | 172 | 0.62 | Why? |
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 143 | 0.62 | Why? |
| Roseolovirus Infections | 1 | 2017 | 131 | 0.61 | Why? |
| Herpesvirus 6, Human | 1 | 2017 | 162 | 0.58 | Why? |
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 2426 | 0.56 | Why? |
| Intestinal Diseases | 1 | 2017 | 231 | 0.54 | Why? |
| Herpesvirus 4, Human | 1 | 2017 | 387 | 0.53 | Why? |
| Vasculitis | 1 | 2020 | 691 | 0.52 | Why? |
| Graft vs Host Disease | 1 | 2017 | 501 | 0.50 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.50 | Why? |
| Luminescent Measurements | 1 | 2017 | 924 | 0.46 | Why? |
| Crohn Disease | 1 | 2020 | 959 | 0.44 | Why? |
| Intestines | 1 | 2017 | 817 | 0.43 | Why? |
| Melanoma | 1 | 2021 | 1229 | 0.41 | Why? |
| Insulin | 1 | 2018 | 1316 | 0.38 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.37 | Why? |
| Immunoassay | 3 | 2021 | 4485 | 0.36 | Why? |
| Tissue Donors | 1 | 2017 | 1679 | 0.34 | Why? |
| T-Lymphocytes | 2 | 2021 | 6670 | 0.33 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.28 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.28 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.26 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.26 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.26 | Why? |
| Pneumonia, Bacterial | 2 | 2021 | 843 | 0.26 | Why? |
| Transplantation, Homologous | 2 | 2017 | 757 | 0.25 | Why? |
| Diagnostic Tests, Routine | 1 | 2014 | 2643 | 0.24 | Why? |
| Internship, Nonmedical | 1 | 2002 | 30 | 0.23 | Why? |
| Education, Pharmacy, Graduate | 1 | 2002 | 24 | 0.23 | Why? |
| Cell Plasticity | 1 | 2021 | 75 | 0.22 | Why? |
| Interleukin-1 Receptor-Associated Kinases | 1 | 2021 | 56 | 0.21 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.21 | Why? |
| Membrane Transport Proteins | 1 | 2021 | 152 | 0.20 | Why? |
| Multiplex Polymerase Chain Reaction | 2 | 2020 | 1439 | 0.19 | Why? |
| Point-of-Care Testing | 3 | 2021 | 2782 | 0.19 | Why? |
| Secretory Pathway | 1 | 2018 | 39 | 0.18 | Why? |
| Epstein-Barr Virus Nuclear Antigens | 1 | 2017 | 7 | 0.18 | Why? |
| Polyomaviridae | 1 | 2017 | 8 | 0.18 | Why? |
| Picobirnavirus | 1 | 2017 | 15 | 0.18 | Why? |
| Anelloviridae | 1 | 2017 | 34 | 0.18 | Why? |
| Bacteriological Techniques | 1 | 2020 | 239 | 0.18 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.18 | Why? |
| Paris | 1 | 2021 | 1287 | 0.17 | Why? |
| Cameroon | 1 | 2018 | 464 | 0.16 | Why? |
| Adenovirus Infections, Human | 1 | 2018 | 145 | 0.16 | Why? |
| Herpesviridae | 1 | 2017 | 100 | 0.16 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.15 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.15 | Why? |
| Interleukins | 1 | 2021 | 762 | 0.15 | Why? |
| Leukocyte L1 Antigen Complex | 1 | 2017 | 238 | 0.15 | Why? |
| Hematopoietic Stem Cells | 1 | 2018 | 321 | 0.15 | Why? |
| Capsid Proteins | 1 | 2017 | 365 | 0.14 | Why? |
| Hematologic Diseases | 1 | 2021 | 614 | 0.14 | Why? |
| alpha 1-Antitrypsin | 1 | 2017 | 264 | 0.14 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.14 | Why? |
| Feces | 2 | 2018 | 4235 | 0.13 | Why? |
| Herpesvirus 2, Human | 1 | 2014 | 137 | 0.13 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.13 | Why? |
| Papillomaviridae | 1 | 2017 | 404 | 0.12 | Why? |
| Bacteria | 2 | 2021 | 1897 | 0.12 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.12 | Why? |
| Dendritic Cells | 1 | 2021 | 1330 | 0.12 | Why? |
| Transplantation Conditioning | 1 | 2014 | 323 | 0.12 | Why? |
| Lymphoma | 1 | 2017 | 522 | 0.11 | Why? |
| Antigens, Viral | 2 | 2020 | 6298 | 0.11 | Why? |
| Lymphocyte Activation | 1 | 2021 | 2742 | 0.11 | Why? |
| Fluorescent Antibody Technique | 1 | 2014 | 835 | 0.11 | Why? |
| Metagenomics | 1 | 2017 | 823 | 0.11 | Why? |
| Herpesvirus 1, Human | 1 | 2014 | 286 | 0.11 | Why? |
| Acyclovir | 1 | 2011 | 154 | 0.11 | Why? |
| Virus Cultivation | 1 | 2014 | 579 | 0.10 | Why? |
| Male | 14 | 2021 | 367725 | 0.10 | Why? |
| Immunocompromised Host | 2 | 2017 | 5150 | 0.10 | Why? |
| Chilblains | 1 | 2021 | 1156 | 0.10 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.10 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.10 | Why? |
| Young Adult | 7 | 2020 | 93724 | 0.10 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.10 | Why? |
| Research | 1 | 2002 | 2115 | 0.09 | Why? |
| Adult | 11 | 2021 | 244371 | 0.09 | Why? |
| High-Throughput Screening Assays | 1 | 2017 | 1783 | 0.09 | Why? |
| Female | 12 | 2021 | 380317 | 0.09 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.09 | Why? |
| Autoimmune Diseases | 1 | 2021 | 1996 | 0.08 | Why? |
| Aged | 9 | 2021 | 215776 | 0.08 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2021 | 3388 | 0.08 | Why? |
| Humans | 23 | 2021 | 930598 | 0.08 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.08 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.07 | Why? |
| Respiratory System | 1 | 2018 | 3213 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.07 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.07 | Why? |
| Immunity, Humoral | 1 | 2017 | 4849 | 0.06 | Why? |
| Host-Pathogen Interactions | 2 | 2021 | 11041 | 0.06 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.05 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.05 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.05 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.05 | Why? |
| Reagent Kits, Diagnostic | 2 | 2021 | 2149 | 0.05 | Why? |
| Pedigree | 1 | 2021 | 502 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Fever | 1 | 2017 | 7795 | 0.05 | Why? |
| Child | 3 | 2018 | 70012 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Polymerase Chain Reaction | 1 | 2014 | 6740 | 0.05 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.05 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.04 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.04 | Why? |
| France | 2 | 2021 | 12074 | 0.04 | Why? |
| Infant | 1 | 2018 | 30274 | 0.04 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.04 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.03 | Why? |
| Respiratory Tract Infections | 1 | 2014 | 6817 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| Data Collection | 1 | 2002 | 1769 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Immunomodulation | 1 | 2021 | 1472 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Equipment Contamination | 1 | 2020 | 1308 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| Pharmacists | 1 | 2002 | 1246 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.03 | Why? |
| Ulcer | 1 | 2011 | 128 | 0.03 | Why? |
| Inflammation Mediators | 1 | 2021 | 2654 | 0.02 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Nucleocapsid Proteins | 1 | 2021 | 3120 | 0.02 | Why? |
| HIV Seropositivity | 1 | 2011 | 320 | 0.02 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.02 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Psoriasis | 1 | 2021 | 1739 | 0.02 | Why? |
| Africa South of the Sahara | 1 | 2011 | 1335 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Attitude of Health Personnel | 1 | 2002 | 4741 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.01 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.01 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| HIV-1 | 1 | 2011 | 3365 | 0.01 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2002 | 43792 | 0.01 | Why? |
| Incidence | 1 | 2014 | 25622 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
Le Goff's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(163)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(200)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_